Comparative genomic analysis of circulating tumor DNA (ctDNA) and paired formalin-fixed paraffin-embedded (FFPE) tissue DNA demonstrated significant genomic concordance in breast cancer patients.
The findings validate the reliability of plasma-based ctDNA profiling as a liquid biopsy approach for detecting tumor-associated genetic alterations.
ctDNA sequencing identified clinically actionable mutations and molecular alterations, providing insights that complement conventional tissue-based genomic testing.
Liquid biopsy analysis also revealed tumor heterogeneity and dynamic genomic changes that may not always be captured through single-site tissue biopsies.
Integration of ctDNA profiling with tissue sequencing offers a more comprehensive understanding of tumor genomics and disease evolution.
The minimally invasive nature of liquid biopsy enables repeated molecular testing, allowing clinicians to track genomic changes over time.
ctDNA monitoring may support real-time evaluation of treatment response, detection of emerging resistance mutations, and early identification of disease progression.
Overall, ctDNA-based genomic profiling complements tissue diagnostics, advancing precision oncology, personalized therapy selection, and longitudinal breast cancer management.
Read Abstract